Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Your search for "swine" return 43 results.
Part 3.1 >
Modified Madec Scoring
Determination of minimal inhibition concentrations of major antibiotics for Streptococcus suis >
The aim of this study was to compare the susceptibility of Streptococcus suis to amoxicillin (AMX) and other frequently used antibiotics in swine, namely ceftiofur (CEF) and marbofloxacin (MAR).
Hyogen® with ImuvantTM - Superior Protection Against Mycoplasma hyopneumoniae infection >
- Single injection provides early and long lasting protection - Broad stimulation of the immune system with ImuvantTM - Trials demonstrate superior protection versus competitors - Expertise of the...
VETRIMOXIN® LA - Technical profile >
Vetrimoxin® LA is the leading product in the Ceva anti-infective range. Within the group of historical antibiotics, the product has an extensive experience in the market as leader in its segment being...
Overview of porcine immune defenses and immunity to Mycoplasma hyopneumoniae infection >
The pig relies on multiple defenses to protect itself against microbial invasion. Understanding these immune defenses will help the producers to find the suitable solution to control the diseases in p...
1. >
Mycoplasma hyopneumoniae
Ceva Lung Program - Overview >
The Ceva Lung Program (CLP) provides an overview of the diseases associated with Actinobacillus pleuropeumoniae, Mycoplasma hyopneumoniae and Aujeszky’s disease virus.
Mycoplasma hyopneumoniae: strain diversity and control measures >
Control measures for infections with Mycoplasma hyopneumoniae should focus on optimisation of management practices, and if these are not sufficient, antimicrobial medication and/or vaccination can be...
Part 3 >
Evaluation of pneumonia and pleurisy
Part 2 >
Actinobacillus pleuropneumoniae